Get the Stockscreener App
1.18
0.00%
0.00
Silo Pharma Inc stock is traded at $1.18, with a volume of 6,574.
It is up +0.00% in the last 24 hours and down -33.33% over the past month.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
See More
Previous Close:
$1.18
Open:
$1.17
24h Volume:
6,574
Relative Volume:
0.20
Market Cap:
$2.42M
Revenue:
$72,100
Net Income/Loss:
$-4.84M
P/E Ratio:
-0.1582
EPS:
-7.4566
Net Cash Flow:
$-3.84M
1W Performance:
+0.00%
1M Performance:
-33.33%
6M Performance:
-83.39%
1Y Performance:
-85.90%
1-Day Range:
$1.17
$1.195
1-Week Range:
$1.13
$1.2324
52-Week Range:
$1.10
$10.43
Silo Pharma Inc Stock (SILO) Company Profile
Name
Silo Pharma Inc
Sector
Industry
Phone
(718) 400-9031
Address
677 N. WASHINGTON BLVD, SARASOTA
Compare SILO vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SILO
Silo Pharma Inc
|
1.18 | 2.42M | 72,100 | -4.84M | -3.84M | -7.4566 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Silo Pharma Inc Stock (SILO) Latest News
Change Agents Corporation Appoints Eric Weisblum as Independent Director - Kalkine Media
Silo Pharma Acquires Software Assets Through Equity Issuance - The Globe and Mail
Silo Pharma Acquires Software and IP Assets From Larry King for 150,000 Shares - TradingView
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Convertible Senior Notes - Investing News Network
Silvia Repurchases an Additional 5% of Shares Outstanding, Bringing Total Repurchases to Approximately 20% - Yahoo Finance
Silo Pharma Acquires IP Assets in Strategic Agreement - The Globe and Mail
A warrant for up to 300,000 shares is Silo Pharma (SILO)'s payment for software assets. - Stock Titan
NVIDIA models join QwikAgents, which adds a second software option for AI assistants. - Stock Titan
Why Is Silo Pharma (NASDAQ:SILO) Moving Into Focus? - Kalkine Media
Silo Pharma Inc (NASDAQ: SILO) Share Price, SILO Stock News, SILO Share Price & Updates - kalkine.com.au
Silo Pharma Highlights Patented Nose-To-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum - marketscreener.com
Silo Pharma to Present at IPAC-RS 2026 Nasal Innovation Forum, Highlighting Progress of PTSD Candidate SPC-15 - citybuzz -
Silo Pharma to Participate in IPAC-RS 2026 Nasal Innovation Forum as It Advances SPC-15 Development - Quiver Quantitative
A nasal PTSD treatment met specs for nine months - Stock Titan
Silo Pharma Stock Price Forecast. Should You Buy SILO? - StockInvest.us
Silo Pharma Inc (NYSE: SILO) Share Price, SILO Stock News, SILO Share Price & Updates - Kalkine
Silo Pharma Inc (SILO) Peer Comparison – Compare with Others - Value Research
Silo Pharma Inc (SILO) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Silo Pharma Acquires Digital Assets via Stock Issuance - The Globe and Mail
Form 8K Silo Pharma Inc For: 19 August By Investing.com - Investing.com South Africa
Form 8K Silo Pharma Inc For: 19 August By Investing.com - Investing.com Nigeria
Silo Pharma Acquires Digital Assets via Stock Issuance - TipRanks
Form 8K Silo Pharma Inc For: 19 August By Investing.com - Investing.com Canada
Form 8K Silo Pharma Inc For: 19 August - Investing.com India
Form 8K Silo Pharma Inc For: 19 August By Investing.com - Investing.com UK
Silo Pharma Acquires Software and IP From Parkview Consulting for 165,000 Shares - TradingView
Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting - TradingView
Silo Pharma (SILO) grants 165K locked-up shares in tech deal - Stock Titan
Silo PharmaEnters Asset Purchase Agreement - Moomoo
SILO 8-K & SEC Filings - Yahoo Finance Australia
Silo Pharma receives Canadian patent allowance for SPC-15 drug By Investing.com - Investing.com Canada
Silo Pharma receives Canadian patent allowance for SPC-15 drug By Investing.com - Investing.com Australia
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment - manilatimes.net
Silo Pharma receives Canadian patent allowance for SPC-15 drug By Investing.com - Investing.com India
Silo Pharma Receives Notice of Allowance for Canadian Patent Application Covering Lead Asset Spc-15 Targeting Ptsd and Other Stress-Induced Psychiatric Disorders - marketscreener.com
Silo (SILO) Technical Check: Adds 1.95% to Close at $3.13; Range and Risk: the $2.97 to $3.29 Range Remains in Focus in the Current UpdateSuperTrend - Vinanet
Silo (SILO) Technical Check: Adds 1.95% to Close at $3.13; Range and Risk: the $2.97 to $3.29 Range Remains in Focus in the Current UpdateCommon Gap - dars.gov.et
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment - GlobeNewswire
Silo Pharma Shareholders Approve Major Share Authorization Expansion - TipRanks
Silo Pharma (SILO) holders approve lifting share cap from 6.7M - Stock Titan
Silo Pharma (SILO) Slips 0.62% to $3.20 as Shares Consolidate Between Key Technical LevelsStock Picks - Vinanet
Silo Pharma (SILO) trims cash burn, mitigates going-concern risk in Q2 2026 - Stock Titan
Silo Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Silo Pharma (SILO) investor group discloses 9.99% warrant-based ownership cap - Stock Titan
Wondering what's happening in today's pre-market session? - ChartMill
Silo Pharma receives European patent for SPC-15 PTSD treatment By Investing.com - Investing.com South Africa
Silo Pharma Granted European Patent Covering Novel PTSD Therapy - The Manila Times
Silo Pharma receives European patent for SPC-15 PTSD treatment - Investing.com India
Silo Pharma receives European patent for SPC-15 PTSD treatment By Investing.com - Investing.com Canada
Silo Pharma Announces European Patent Grant for SPC-15 PTSD Prevention Therapy - Quiver Quantitative
Silo Pharma Inc Stock (SILO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Silo Pharma Inc Stock (SILO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | Chief Executive Officer |
Nov 21 '25 |
Buy |
0.36 |
1,000 |
365 |
211,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 20 '25 |
Buy |
0.37 |
1,000 |
370 |
210,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 19 '25 |
Buy |
0.41 |
4,500 |
1,823 |
209,932 |
| Weisblum Eric | Chief Executive Officer |
Nov 18 '25 |
Buy |
0.40 |
7,500 |
3,025 |
205,432 |
3.09%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):